LataMed AI Corp. (OTC: LMED), a healthcare technology company specializing in digital health and artificial intelligence solutions for Latin America, announced on August 3, 2026, that its Venezuelan subsidiary, LATAMEDAI VE, has signed an agreement with DROGUERIAS LALA C.A. to collaboratively develop AI-supported and automated software tools for pharmaceutical and laboratory workflows. This strategic partnership is set to address critical operational challenges in the region's pharmaceutical sector.
The collaboration will focus on designing, developing, testing, and evaluating customized technology to support selected workflows, including pharmaceutical research, laboratory testing, quality control, documentation, operational coordination, and data analysis. The proposed software is expected to incorporate features such as workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytics. These tools aim to help qualified personnel identify potential inconsistencies or operational issues at an earlier stage, thereby enhancing efficiency and reliability.
Under the agreement, LataMed AI and DROGUERIAS LALA will begin by identifying specific workflows to be addressed, defining technical and operational requirements, and establishing a phased development and testing process. They will also implement robust confidentiality, information-security, data-management, and access-control procedures to safeguard sensitive information.
The technology is designed as a decision-support and workflow-management resource, not as an independent approver of pharmaceutical formulas, laboratory results, or regulatory submissions. All scientific and regulatory determinations will remain the responsibility of qualified professionals and regulatory authorities. This ensures that the AI tools augment rather than replace human expertise.
Dr. Kevin Rodan Levy, CEO of LataMed AI, emphasized the significance of the agreement: “This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight.”
Management believes this collaboration could expand LataMed AI's technology into enterprise pharmaceutical and laboratory applications, extending beyond its patient-facing telemedicine services. It aligns with the company's broader strategy of developing digital infrastructure and AI-supported tools for healthcare providers, pharmacies, laboratories, and other ecosystem participants.
If successfully developed, the technology could potentially be adapted for other pharmaceutical and healthcare organizations in Venezuela and Latin America. However, any future expansion would depend on separate agreements, successful development and testing, operational readiness, regulatory compliance, and organizational needs.
The parties will also evaluate ownership, licensing, and intellectual-property protection for any software or data developed. The specific terms will be governed by the agreement and additional documentation.
This agreement sets the framework for collaboration but does not guarantee a specific implementation schedule, commercial deployment, cost reductions, scientific outcomes, or revenue. The company will provide updates as development progresses.
For more information, visit https://latamed.ai or review SEC filings at www.sec.gov.
